Adipose most abundant 2 protein is a predictive marker for cisplatin sensitivity in cancers
Abstract Cisplatin (CDDP) is one of the chemotherapeutic drugs being used to treat various cancers. Although effective in many cases, as high doses of CDDP cause cytotoxic effects that may worsen patients’ condition, therefore, a marker of sensitivity to CDDP is necessary to enhance the safety and e...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/79557776ef4640ec831b2db676818deb |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:79557776ef4640ec831b2db676818deb |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:79557776ef4640ec831b2db676818deb2021-12-02T17:05:46ZAdipose most abundant 2 protein is a predictive marker for cisplatin sensitivity in cancers10.1038/s41598-021-85498-72045-2322https://doaj.org/article/79557776ef4640ec831b2db676818deb2021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-85498-7https://doaj.org/toc/2045-2322Abstract Cisplatin (CDDP) is one of the chemotherapeutic drugs being used to treat various cancers. Although effective in many cases, as high doses of CDDP cause cytotoxic effects that may worsen patients’ condition, therefore, a marker of sensitivity to CDDP is necessary to enhance the safety and efficiency of CDDP administration. This study focused on adipose most abundant 2 (APM2) to examine its potential as a marker of CDDP sensitivity. The relationship of APM2 expression with the mechanisms of CDDP resistance was examined in vitro and in vivo using hepatocellular carcinoma (HCC) cells, tissues and serum of HCC patients (n = 71) treated initially with intrahepatic arterial infusion of CDDP followed by surgical resection. The predictability of serum APM2 for CDDP sensitivity was assessed in additional 54 HCC patients and 14 gastric cancer (GC) patients. APM2 expression in CDDP-resistant HCC was significantly higher both in serum and the tissue. Bioinformatic analyses and histological analyses demonstrated upregulation of ERCC6L (DNA excision repair protein ERCC6-like) by APM2, which accounts for the degree of APM2 expression. The serum APM2 level and chemosensitivity for CDDP were assessed and cut-off value of serum APM2 for predicting the sensitivity to CDDP was determined to be 18.7 µg/mL. The value was assessed in HCC (n = 54) and GC (n = 14) patients for its predictability of CDDP sensitivity, resulted in predictive value of 77.3% and 100%, respectively. Our study demonstrated that APM2 expression is related to CDDP sensitivity and serum APM2 can be an effective biomarker of HCC and GC for determining the sensitivity to CDDP. Trial registration: This study was registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN000028487).Kenya KamimuraTakeshi SudaYasuo FukuharaShujiro OkudaYu WatanabeTakeshi YokooAkihiko OsakiNobuo WaguriToru IshikawaToshihiro SatoYutaka AoyagiMasaaki TakamuraToshifumi WakaiShuji TeraiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-15 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Kenya Kamimura Takeshi Suda Yasuo Fukuhara Shujiro Okuda Yu Watanabe Takeshi Yokoo Akihiko Osaki Nobuo Waguri Toru Ishikawa Toshihiro Sato Yutaka Aoyagi Masaaki Takamura Toshifumi Wakai Shuji Terai Adipose most abundant 2 protein is a predictive marker for cisplatin sensitivity in cancers |
| description |
Abstract Cisplatin (CDDP) is one of the chemotherapeutic drugs being used to treat various cancers. Although effective in many cases, as high doses of CDDP cause cytotoxic effects that may worsen patients’ condition, therefore, a marker of sensitivity to CDDP is necessary to enhance the safety and efficiency of CDDP administration. This study focused on adipose most abundant 2 (APM2) to examine its potential as a marker of CDDP sensitivity. The relationship of APM2 expression with the mechanisms of CDDP resistance was examined in vitro and in vivo using hepatocellular carcinoma (HCC) cells, tissues and serum of HCC patients (n = 71) treated initially with intrahepatic arterial infusion of CDDP followed by surgical resection. The predictability of serum APM2 for CDDP sensitivity was assessed in additional 54 HCC patients and 14 gastric cancer (GC) patients. APM2 expression in CDDP-resistant HCC was significantly higher both in serum and the tissue. Bioinformatic analyses and histological analyses demonstrated upregulation of ERCC6L (DNA excision repair protein ERCC6-like) by APM2, which accounts for the degree of APM2 expression. The serum APM2 level and chemosensitivity for CDDP were assessed and cut-off value of serum APM2 for predicting the sensitivity to CDDP was determined to be 18.7 µg/mL. The value was assessed in HCC (n = 54) and GC (n = 14) patients for its predictability of CDDP sensitivity, resulted in predictive value of 77.3% and 100%, respectively. Our study demonstrated that APM2 expression is related to CDDP sensitivity and serum APM2 can be an effective biomarker of HCC and GC for determining the sensitivity to CDDP. Trial registration: This study was registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN000028487). |
| format |
article |
| author |
Kenya Kamimura Takeshi Suda Yasuo Fukuhara Shujiro Okuda Yu Watanabe Takeshi Yokoo Akihiko Osaki Nobuo Waguri Toru Ishikawa Toshihiro Sato Yutaka Aoyagi Masaaki Takamura Toshifumi Wakai Shuji Terai |
| author_facet |
Kenya Kamimura Takeshi Suda Yasuo Fukuhara Shujiro Okuda Yu Watanabe Takeshi Yokoo Akihiko Osaki Nobuo Waguri Toru Ishikawa Toshihiro Sato Yutaka Aoyagi Masaaki Takamura Toshifumi Wakai Shuji Terai |
| author_sort |
Kenya Kamimura |
| title |
Adipose most abundant 2 protein is a predictive marker for cisplatin sensitivity in cancers |
| title_short |
Adipose most abundant 2 protein is a predictive marker for cisplatin sensitivity in cancers |
| title_full |
Adipose most abundant 2 protein is a predictive marker for cisplatin sensitivity in cancers |
| title_fullStr |
Adipose most abundant 2 protein is a predictive marker for cisplatin sensitivity in cancers |
| title_full_unstemmed |
Adipose most abundant 2 protein is a predictive marker for cisplatin sensitivity in cancers |
| title_sort |
adipose most abundant 2 protein is a predictive marker for cisplatin sensitivity in cancers |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/79557776ef4640ec831b2db676818deb |
| work_keys_str_mv |
AT kenyakamimura adiposemostabundant2proteinisapredictivemarkerforcisplatinsensitivityincancers AT takeshisuda adiposemostabundant2proteinisapredictivemarkerforcisplatinsensitivityincancers AT yasuofukuhara adiposemostabundant2proteinisapredictivemarkerforcisplatinsensitivityincancers AT shujirookuda adiposemostabundant2proteinisapredictivemarkerforcisplatinsensitivityincancers AT yuwatanabe adiposemostabundant2proteinisapredictivemarkerforcisplatinsensitivityincancers AT takeshiyokoo adiposemostabundant2proteinisapredictivemarkerforcisplatinsensitivityincancers AT akihikoosaki adiposemostabundant2proteinisapredictivemarkerforcisplatinsensitivityincancers AT nobuowaguri adiposemostabundant2proteinisapredictivemarkerforcisplatinsensitivityincancers AT toruishikawa adiposemostabundant2proteinisapredictivemarkerforcisplatinsensitivityincancers AT toshihirosato adiposemostabundant2proteinisapredictivemarkerforcisplatinsensitivityincancers AT yutakaaoyagi adiposemostabundant2proteinisapredictivemarkerforcisplatinsensitivityincancers AT masaakitakamura adiposemostabundant2proteinisapredictivemarkerforcisplatinsensitivityincancers AT toshifumiwakai adiposemostabundant2proteinisapredictivemarkerforcisplatinsensitivityincancers AT shujiterai adiposemostabundant2proteinisapredictivemarkerforcisplatinsensitivityincancers |
| _version_ |
1718381797562122240 |